FLAGSTAFF, Ariz., March 18, 2019 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, confirmed news reports that the City's Gateway Arch Park Foundation will continue and expand their use of ContraPest as the City of St. Louis embraces the role fertility control plays in integrated pest management.
"While onsite this past Friday, March 15th, I was pleased to provide comments to KMOV (a CBS affiliate) in St. Louis for a special piece on our success in rat management with ContraPest in the City. SenesTech has been dedicated to urban rodent issues since our very first trial," said Brandy Pyzyna, Vice President of Scientific Operations of SenesTech.
The St. Louis metropolitan area is a major inland port and home to approximately 3 million people. The city is well know for aggressively addressing urban problems, such as air pollution in the first part of the 20th century. In 2006 St. Louis won the World Leadership Award for urban renewal. "It is no surprise that St. Louis continues their commitment to excellence in city management and choosing ContraPest is yet another step forward into the future. We are proud to be a part of their thoughtful leadership," said Dr. Loretta Mayer, CEO of SenesTech, "and yes, their vision from the top of the Arch."
"Perhaps more is known about urban rats by the pest management industry as a whole, however, the role of fertility control is novel and actually accelerated in such areas where food, water, and shelter are in abundance. The complete integrated approach to reducing rodent pests is dependent on working together with communities that are dedicated to providing that sound science to our industry colleagues," said Terry Hoselton, owner of Missouri Pest Consultants (MPC) and project manager of the St. Louis deployment. "The City has further expanded the use of ContraPest into other structures throughout the city."
SenesTech is changing the paradigm of pest management by targeting the root cause of the problem: reproduction.
ContraPest® is an innovative technology with an approach that targets the reproductive capabilities of both sexes in rat populations, inducing egg loss in female rats and impairing sperm development in males. Using a proprietary bait delivery method, ContraPest® is dispensed in a highly palatable liquid formulation that promotes sustained consumption by rat communities. ContraPest® is designed, formulated and dispensed to be low hazard for handlers and non-target species such as wildlife, livestock and pets, where the active ingredients break down rapidly.
We believe ContraPest® will establish a new paradigm in rodent control, resulting in a decreased reliance on lethal options. For more information visit the SenesTech website at www.senestech.com.
Safe Harbor Statement
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in our filings with the Securities and Exchange Commission. Forward looking statements include, but are not limited to, our expectation regarding sales commitments, our expectation regarding the conversion of sales commitments and programs to revenue, our belief that our product is more humane, less harmful to the environment and more effective than traditional methods, and our belief that ContraPest will establish a new paradigm in rodent control without environmental effects of rodenticides. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
Investor: Robert Blum, Joe Dorame, Joe Diaz, Lytham Partners, LLC, 602-889-9700, firstname.lastname@example.org
Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143